Media stories about Enzymotec (NASDAQ:ENZY) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzymotec earned a news impact score of 0.21 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.7852081614542 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
Shares of Enzymotec (ENZY) opened at 11.25 on Friday. The firm’s market capitalization is $258.18 million. The company’s 50-day moving average is $11.31 and its 200 day moving average is $9.40. Enzymotec has a 52-week low of $5.20 and a 52-week high of $12.35.
Enzymotec (NASDAQ:ENZY) last released its quarterly earnings data on Wednesday, August 16th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.15). The firm had revenue of $13.00 million for the quarter, compared to the consensus estimate of $12.78 million. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.04 earnings per share. Equities analysts expect that Enzymotec will post $0.14 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. ValuEngine raised shares of Enzymotec from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Finally, Jefferies Group LLC restated a “hold” rating and set a $11.50 price objective on shares of Enzymotec in a research report on Thursday, October 19th. Four analysts have rated the stock with a hold rating, Enzymotec has a consensus rating of “Hold” and a consensus price target of $11.50.
COPYRIGHT VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/enzymotec-enzy-earns-news-impact-score-of-0-21.html.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.